Oppenheimer raised the firm’s price target on Aquestive Therapeutics (AQST) to $8 from $7 and keeps an Outperform rating on the shares. The firm notes that last week, Aquestive announced that the FDA would not require an AdCom for its NDA of Anaphylm sending shares up +43.77% as investors interpret the update increasing the chances of approval. While Oppenheimer saw an AdCom as likely and increasing the path to approval given the established approval path with neffy and Analphylm’s novel route of administration, it appears the data package submitted suffices in guiding the FDA on addressing key topics for potential approval without the need for expert recommendations.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics: De-risking and Strategic Positioning for Success in the Type 1 Allergy Market
- Salesforce slides, Figma flops after earnings: Morning Buzz
- Buy Rating Reiterated for Aquestive Therapeutics: Favorable FDA Outlook and Strong Market Potential for Anaphylm
- Aquestive Therapeutics Awaits FDA Decision on Anaphylm
- Aquestive announces FDA to not require advisory committee meeting for Anaphylm